Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Aliperta, R."'
1
Redirection of human T lymphocytes armed with on/off switchable universal chimeric antigen receptors against various malignant cells
Autor: Feldmann, A., Bergmann, R., Albert, S., Metwasi, N., Arndt, C., Aliperta, R., Koristka, S., Ehninger, A., Cartellieri, M., Ehninger, G., Steinbach, J., Bachmann, M.
Publikováno v: Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, 06.-09.09.2017, Mainz, Deutschland
Recently, chimeric antigen receptor (CAR) expressing T cells have shown tremendous clinic effects in several cancer patients. However once those genetically modified T cells are adoptively transferred in a patient their reactivity cannot be controlle
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::837919621433e91220694aff28ccd17e
https://www.hzdr.de/publications/Publ-26021-2
Zobrazit plný text záznamu
2
Antigen-specific redirection of human regulatory T cells via a universally applicable chimeric antigen receptor technology
Autor: Kegler, A., Koristka, S., Feldmann, A., Arndt, C., Aliperta, R., Albert, S., Ziller-Walter, P., Ehninger, G., Bornhäuser, M., Schmitz, M., Bachmann, M.
Publikováno v: Cellular Therapy 2017, 9th International Symposium Erlangen, 16.-17.03.2017, Erlangen, Deutschland
Regulatory T cells (Tregs) play a fundamental role in preventing inflammatory diseases and, therefore, their adoptive transfer emerged as a promising therapeutic strategy for the treatment of autoimmunity, graft rejection and Graft-versus-Host diseas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::57924416db65d0c2568e512c3bd3297e
https://www.hzdr.de/publications/Publ-25246-1
Zobrazit plný text záznamu
3
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
Autor: Bachmann, D., Aliperta, R., Bergmann, R., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Welzel, P. B., Albert, S., Kegler, A., Ehninger, A., Cartellieri, M., Ehninger, G., Bornhäuser, M., Bonin, M., Werner, C., Pietzsch, J., Steinbach, J., Bachmann, M.
Publikováno v: Oncotarget 9(2017), 7487-7500
Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::584fdde730f5666d80dbe849332e5fb0
https://www.hzdr.de/publications/Publ-26281-1
Zobrazit plný text záznamu
4
Universal CAR technology for redirection of human T cells to leukemic and solid tumor cells
Autor: Feldmann, A., Bergmann, R., Albert, S., Arndt, C., Aliperta, R., Koristka, S., Ehninger, A., Cartellieri, M., Ehninger, G., Steinbach, J., Bachmann, M.
Publikováno v: Cellular Therapy 2017, 9th International Symposium Erlangen, 16.-17.03.2017, Erlangen, Deutschland
In recent years, adoptively transferred autologous human T cells that are genetically modified with chimeric antigen receptors (CARs) have been very successfully used for treatment of different hematological malignancies. However, immunotherapy of so
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::cd9326cd848f08723d7af0b3896ff023
https://www.hzdr.de/publications/Publ-25247-1
Zobrazit plný text záznamu
6
Redirection of human T cells to tumor cells via nanobody-based target modules using the universal chimeric antigen receptor system
Autor: Albert, S., Bergmann, R., Koristka, S., Feldmann, A., Arndt, C., Aliperta, R., Ehninger, A., Cartellieri, M., Ehninger, G., Steinbach, J., Bachmann, M.
Publikováno v: Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, 06.09.2017, Mainz, Deutschland
In general, adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells has an impressive immunotherapeutic potential. However, due to the time-consuming establishment of new CAR constructs, the risk of life-threatening side effects, and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::64e236f5ec3437c70201bf50d5584088
https://www.hzdr.de/publications/Publ-26020-1
Zobrazit plný text záznamu
7
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology 'UniCAR'
Autor: Feldmann, A., Arndt, C., Bergmann, R., Loff, S., Cartellieri, M., Bachmann, D., Aliperta, R., Hetzenecker, M., Ludwig, F., Albert, S., Ziller-Walter, P., Kegler, A., Koristka, S., Gärtner, S., Schmitz, M., Ehninger, A., Ehninger, G., Pietzsch, J., Steinbach, J., Bachmann, M.
Publikováno v: Oncotarget 8(2017)19, 31368-31385
New treatment options especially of solid tumors including for metastasized prostate cancer (PCa) are urgently needed. Recent treatments of leukemias with chimeric antigen receptors (CARs) underline their impressive therapeutic potential. However CAR
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::a561969ebb7cf53b1cdaf00e319a7809
https://www.hzdr.de/publications/Publ-24798-1
Zobrazit plný text záznamu
9
The costimulatory domain in CAR T cells determines the resistance to immunosuppression by regulatory T cells
Autor: Kegler, A., Koristka, S., Bergmann, R., Feldmann, A., Arndt, C., Aliperta, R., Albert, S., Ziller-Walter, P., Ehninger, G., Bornhäuser, M., Schmitz, M., Bachmann, M.
Publikováno v: Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, 06.09.2017, Mainz, Germany
Chimeric antigen receptor (CAR)-modified T cells are intensively studied for their application in cancer patients and already proved incredible success in clinical trials. However, the choice of the intracellular signaling domain integrated into the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::a0b6fd464e934ac1522e15e5ac1a8992
https://www.hzdr.de/publications/Publ-26022-1
Zobrazit plný text záznamu
10
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts
Autor: Aliperta, R., Cartellieri, M., Feldmann, A., Arndt, C., Koristka, S., Michalk, I., Bonin, M., Ehninger, A., Bachmann, J., Ehninger, G., Bornhäuser, M., Bachmann, M. P.
Publikováno v: Blood Cancer Journal 5(2015), e348
Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. Because their low molecular mass, bsAbs have short half-lives. To achieve clinical responses, they have t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::733e86b49351ee35b64aa1b317352724
https://www.hzdr.de/publications/Publ-22361-1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje